Sign inJoin waitlistJoin the waitlist

Leslie Bradford

Physician · MaineHealth - Maine Medical Center

Credentials: · · · · · ·

History

MaineHealth - Maine Medical Center
2021–Present

Gynecologic Oncology
Massachusetts General Hospital
2010–2013
Obstetrics and Gynecology
University of Wisconsin Hospitals and Clinics
2006–2010
Robert Larner College of Medicine
2002–2006

Research

Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma
Gynecologic Oncology · 2013 · 95 citations
Advances in the management of recurrent endometrial cancer
Review · American Journal of Clinical Oncology · 2015 · First of 5 authors · 73 citations
Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis
Gynecologic Oncology · 2013 · 56 citations

John Schorge
11 papers
Annekathryn Goodman
9 papers
David Boruta
9 papers
Jose Rauh-Hain
9 papers · 9 as a fellow
Marcela del Carmen
8 papers · 1 as a resident
Rachel Sisodia
8 papers · 8 as a resident
Whitfield Growdon
7 papers
Yuxin Liu
4 papers
Amy Brown
3 papers
AS
Ashley Stuckey
3 papers
Disha Dalela
3 papers · 3 as a resident
EH
Erin Hofstatter
3 papers · 2 as a resident

Grants

MaineHealth Cancer Care Network (MHCCN) and NCORP Activities Across the Lifespan
National Cancer Institute · UG1
PI · $7M · Mainehealth
2019–2027

Clinical trials

Endometrial Cancer Vaginal Fluid Specimen Collection Study
Site PI · Recruiting
Exact Sciences Corporation
2026–2028
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028
Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study
Site PI · Recruiting
Wake Forest University Health Sciences
2026–2027
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030